Table 5. Adverse events related to TACE for the two treatment groups.

Adverse events	TACE + sorafenib n = 103, n (%) n (%)	TACE n = 133	X2 value	P-value
Major Adverse Events
Upper GI bleeding	2 (1.9)	2 (1.5)		1.000*
Biloma with abscess	1 (1.0)	3 (2.3)		0.634*
Minor Adverse Events
Abdominal pain	74 (71.8)	91 (68.4)	0.323	0.570
fever	73 (70.9)	98 (73.6)	0.688	0.407
vomiting	41 (39.8)	59 (44.4)	0.493	0.482
1-2 myelosuppression	4 (3.8)	5 (3.7)		1.000*

TACE, transcatheter arterial chemoembolization; GI, gastrointestinal; ^*Fisher’s Exact Test was used.